Incyte Named a 2018 Top Employer by Science Magazine
Incyte Corporation (Nasdaq:INCY) announced today that it has been named one of the global biotechnology and pharmaceutical industry’s top employers by Science magazine, ranking second on the list of only 20 companies recognized in the publication’s annual Top Employer’s Survey.
“We are proud to be recognized as the number two top employer in the biopharma industry by Science magazine and, importantly, also by our own team,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “We believe that the collective experience and passion of our over 1,300 talented colleagues is foundational to our success, and as our organization continues to grow, we are committed to maintaining a culture that is driven by a passion for innovative science and where patients are at the forefront of everything we do. Together, we strive to make a meaningful difference in the lives of patients with cancer and other serious diseases.”
The Science and Science Careers’ 2018 annual Top Employers Survey polled employees in biotechnology, pharmaceutical and related industries to determine the 20 best employers in these industries as well as their driving characteristics. Respondents were asked to evaluate companies based on 23 different characteristics, including financial strength, easy adaptation to change and a research-driven environment. Incyte was specifically recognized by its team members for its innovation, work culture and respect for employees.
According to Science, the 2018 rankings were based on a total sample of more than 8,000 respondents from North America (63 percent), Europe (24 percent) and Asia/Pacific Rim (9 percent).
The complete survey feature along with individual company rankings is available in the October 26, 2018, print issue of Science, and online: http://www.sciencemag.org/features/2018/10/top-employers-embrace-change-based-stable-foundation.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181025005872/en/